Navigation Links
Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
Date:9/3/2008

SB-509 to be Evaluated in Repeat-Dosing Study in Subjects with ALS

RICHMOND, Calif., Sept. 3 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that it has opened a Phase 2 clinical trial (SB-509-801) to evaluate its drug, SB-509, in subjects with ALS, a progressive, degenerative motor-neuron disease for which there are limited treatment options and no cure.

Sangamo's drug, SB-509, is an injectable formulation of a plasmid encoding a zinc finger DNA-binding protein transcription factor (ZFP TF(TM)) designed to upregulate the expression of the gene encoding vascular endothelial growth factor (VEGF-A). SB-509 is also in three additional Phase 2 clinical trials for diabetic neuropathy and stem cell mobilization. VEGF-A has been shown to have nerve protection properties as well as promoting nerve, blood vessel and muscle growth.

In ALS, the motor nerves comprised of nerve cells in the brain and spinal cord that control the body's voluntary muscles, gradually degenerate. As the nerve cells begin to die, the muscles weaken and shrink. As the disease progresses, patients gradually lose the use of their limb and neck muscles, ultimately becoming paralyzed and unable to breathe without assistance. Fifty percent of patients with ALS die within three to five years of diagnosis. Currently, there is only one approved drug for ALS; Riluzole has been demonstrated to slow the progression of this debilitating disease with only modest clinical benefit, extending the survival of ALS patients by approximately three months.

"Initiation of a Phase 2 clinical study of SB-509 in subjects with a motor neuron and muscle disease such as ALS is an obvious next step in the evaluation of this novel therapeut
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
2. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
3. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
4. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
5. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
6. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
7. Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
8. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells
9. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
10. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
11. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... NEW YORK , May 22, 2013 ... Gross LLP is investigating claims on behalf of investors ... (NASDAQ: ISRG ) (CUSIP: 46120E602) who purchased ... April 18, 2013 (the "Class Period"). Such investors are ... at rswilloughby@pomlaw.com or 888-476-6529, ext. 237. ...
(Date:5/22/2013)... Z-Medica, a leading developer and marketer of ... line of products designed to meet the unique needs ... EMS 4x4 Dressing, QuikClot ® EMS TraumaPad ... all custom-designed to help responders stop bleeding fast and ... a hospital or trauma center. The line includes products ...
(Date:5/22/2013)... , May 22, 2013 STEPh, Inc., ... announce the launch of their web site ( ... Reports].  About STEPh Reports ... development.  Each STEPh Report assesses the ... data, projected launch year, company, and specific key issues.  ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intuitive Surgical, Inc. - ISRG 2Z-Medica Launches New Line of Hemostatic Agents for use in Emergency Medical Services 2Scientific and Technical Evaluation of Pharmaceuticals, Inc. [STEPh, Inc.], Launches New Competitive Intelligence Web Site 2
... TOKYO and CHIPPENHAM, England, October 7 ,Sosei ... and Vectura,Group plc ("Vectura"; LSE: VEC), announce ... efficacy, safety and tolerability of NVA237 presented ... Society (ERS) in Berlin,Germany. The new data ...
... of Gastroenterology Annual ... ... two Phase 3,studies presented at the American College of Gastroenterology Annual,Scientific ... rates than lansoprazole among patients with more,severe grades of erosive esophagitis ...
Cached Medicine Technology:NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 2NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 3NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 4NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 5Takeda's Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed 2Takeda's Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed 3
(Date:5/22/2013)... Rochester, NY (PRWEB) May 22, 2013 ... can now have access to Adapt Courseware’s new ... curriculum in an adaptive framework that responds based ... Adapt Courseware , the provider of comprehensive adaptive ... experience, is continuing to develop introductory level general ...
(Date:5/22/2013)... Jersey (PRWEB) May 22, 2013 Ethos ... gift card system, fit for the busy lifestyle of the ... select a design appropriate for the occasion, whether it is ... an apology note, or any other occasion. , Clients should ... Jersey spa gift card designs on the Ethos Spa’s ...
(Date:5/22/2013)... TheBeautyPlace.com features Toppik and Bosley hair fibers, two ... of thinning or balding hair. Hair loss treatments can be ... hair loss during this waiting period, one can use these ... alternative to hair transplant surgery in general. , Bosley ... extremely effective way to eliminate the appearance of balding and ...
(Date:5/22/2013)... NJ (PRWEB) May 22, 2013 The health ... In some states, up to twenty-seven percent of all ... all bankruptcies of private citizens in the U.S. are related ... also affects prescription drugs, meaning that many patients cannot afford ... even get them filled at all. That's why MedicationDiscountCard.com ...
(Date:5/22/2013)... NJ (PRWEB) May 22, 2013 Officials ... today that its cicada services are now in full ... year that the cicada cycle emerges. , “The ... the year that they will emerge, so we’re now ... they are well protected during the invasion,” said R. ...
Breaking Medicine News(10 mins):Health News:Adapt Courseware Releases Introduction to Sociology for Colleges and Universities Nationwide 2Health News:Adapt Courseware Releases Introduction to Sociology for Colleges and Universities Nationwide 3Health News:Ethos Spa Skin And Laser Center Has Launched Their Customizable Gift Certificates 2Health News:TheBeautyPlace.com Divulges Two Innovative Hair Loss Concealers on the Market Today: Bosley Hair Thickening Fibers and Toppik Hair Building Fibers 2Health News:Lyrica Discount Cards Now Available From MedicationDiscountCard.com 2Health News:Alliance Commercial Pest Control, Inc. Now Offering Cicada Protection Services 2
... researcher has co-authored an international study that revealed a drug ... a rare lung disease in women. The life-threatening disease ... The clinical trial of the drug -- called sirolimus -- ... therapy for the lung disease, lymphangioleiomyomatosis, or LAM. LAM ...
... The wrist size of overweight or obese children and teens ... says a new study. Italian researchers measured the wrist ... They also used a painless nuclear imaging technique on about ... areas of the wrist more precisely. Blood tests were ...
... MONDAY, April 11 (HealthDay News) -- A drug commonly prescribed ... treating the mild stage of the disease, a new study ... effective in treating moderate to severe Alzheimer,s disease, "in mild ... works," said lead researcher Dr. Lon S. Schneider, a professor ...
... new discovery published online in The FASEB Journal ( ... likely to benefit from breast cancer drug therapies. If ... it would represent a significant advance for breast cancer ... some people. In addition, some drugs have side effects ...
... How your carotid artery moves can reveal your risk of ... study this vessel aspect in more detail thanks to a ... with suspected coronary artery disease, reveals a thesis from the ... arteries is associated with a risk of future heart disease, ...
... the journal Investigational New Drugs and conducted by researchers ... molecule inhibitors are showing promise in blocking STAT3, a ... osteosarcoma. These small molecule inhibitors one derived from ... as a new, non-toxic treatment for these deadly tumors. ...
Cached Medicine News:Health News:OHSU expert co-authors study finding treatment for rare lung disease 2Health News:Drug Memantine Ineffective for Mild Alzheimer's, Study Finds 2Health News:Drug Memantine Ineffective for Mild Alzheimer's, Study Finds 3Health News:Tiny antibody fragments raised in camels find drug targets in human breast cancer cells 2Health News:New potential atherosclerosis risk marker discovered 2Health News:New study finds compounds show promise in blocking STAT3 signaling as treatment for osteosarcoma 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: